Table 2.
Significant data and outcomes at 6 months after kidney transplantation.
| uPEC+ | uPEC- | P-value | |
|---|---|---|---|
| n = 41 | n = 25 | ||
| DGF (Y/N) | 7/34 | 3/22 | 0.73 |
| Acute rejection (Y/N) | 3/38 | 0/25 | 0.28 |
| Corticosteroids (Y/N) | 38/3 | 23/2 | 0.99 |
| Hypertension (Y/N) | 18/23 | 7/18 | 0.29 |
| RAS Blockade (Y/N) | 4/37 | 1/24 | 0.64 |
| BMI (kg/m2) | 25.8 ± 4.7 | 27.2 ± 4.5 | 0.25 |
| Diabetes (Y/N) | 6/35 | 5/20 | 0.11 |
| Calcidiol (ng/mL) | 56.8 ± 26.4 | 40.0 ± 20.1 | 0.25 |
| Vitamin D/VDRA (Y/N) | 13/28 | 8/17 | 0.99 |
| eGFR (CKD-EPI) mL/min/1.73 m2 | 56.0 ± 16.5 | 59.3 ± 19.1 | 0.47 |
| Proteinuria (g/mol) | 16.1 ± 12.7 | 13.2 ± 13.4 | 0.38 |
| Albuminuria (g/mol) | 7.1 ± 10.2 | 3.3 ± 5.8 | 0.11 |
| HLA-DSA (Y/N) | 3/38 | 2/23 | 0.55 |
| T-cell ELISPOT | 28 ± 70 | 20 ± 19 | 0.62 |
DGF, delayed graft function; RAS, renin angiotensin system; BMI, body mass index; VDRA, vitamin D receptor agonist; eGFR, estimated glomerular filtration rate; HLA-DSA, human leukocyte antigen-donor specific antibodies.